These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 28389457)
1. Reviewing concomitant medications for participants in oncology clinical trials. McGahey KE; Weiss GJ Am J Health Syst Pharm; 2017 Apr; 74(8):580-586. PubMed ID: 28389457 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials. Marcath LA; Coe TD; Hoylman EK; Redman BG; Hertz DL BMC Cancer; 2018 Nov; 18(1):1155. PubMed ID: 30466416 [TBL] [Abstract][Full Text] [Related]
3. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs. Venkatakrishnan K; Pickard MD; von Moltke LL Clin Pharmacokinet; 2010 Nov; 49(11):703-27. PubMed ID: 20923246 [TBL] [Abstract][Full Text] [Related]
4. Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials. Ranchon F; Vial T; Rioufol C; Hénin E; Falandry C; Freyer G; Trillet-Lenoir V; Le Tourneau C; You B Crit Rev Oncol Hematol; 2015 May; 94(2):189-200. PubMed ID: 25638703 [TBL] [Abstract][Full Text] [Related]
5. Mitigating the Risk of Drug Interactions in Cancer Patients Taking Oral Anticancer Agents: The Role of a Multidisciplinary Team-Based Medication Reconciliation. Rodrigues J; Marques P; Gomes C; Portela C Cureus; 2023 Feb; 15(2):e35324. PubMed ID: 36994248 [TBL] [Abstract][Full Text] [Related]
6. Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents. Chuk MK; Mulugeta Y; Roth-Cline M; Mehrotra N; Reaman GH Clin Cancer Res; 2017 Jan; 23(1):9-12. PubMed ID: 27780857 [TBL] [Abstract][Full Text] [Related]
7. American society of clinical oncology - 45th annual meeting. Part 2. Lakeram M; Kibble A IDrugs; 2009 Jul; 12(7):404-8. PubMed ID: 19579155 [No Abstract] [Full Text] [Related]
8. American society of clinical oncology - 45th annual meeting. Part 1. Gale S IDrugs; 2009 Jul; 12(7):401-3. PubMed ID: 19579154 [No Abstract] [Full Text] [Related]
9. American Society of Clinical Oncology--44th Annual Meeting. Reports of clinical trial results--part 1. Searle B IDrugs; 2008 Aug; 11(8):545-6. PubMed ID: 18683083 [No Abstract] [Full Text] [Related]
10. Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy. Marcath LA; Finley CM; Wong SF; Hertz DL BMC Cancer; 2021 Mar; 21(1):324. PubMed ID: 33771105 [TBL] [Abstract][Full Text] [Related]
11. American Society of Clinical Oncology--44th Annual Meeting. Reports of clinical trial results--part 2. Ogbighele E IDrugs; 2008 Aug; 11(8):547-9. PubMed ID: 18683084 [No Abstract] [Full Text] [Related]
12. American Society of Clinical Oncology--44th Annual Meeting. Target identification and data from preclinical and clinical studies. Kibble A IDrugs; 2008 Aug; 11(8):541-4. PubMed ID: 18683082 [No Abstract] [Full Text] [Related]
13. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Chan A; Tan SH; Wong CM; Yap KY; Ko Y Clin Ther; 2009; 31 Pt 2():2379-86. PubMed ID: 20110047 [TBL] [Abstract][Full Text] [Related]
14. Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. Olin JL; Klibanov O; Chan A; Spooner LM Ann Pharmacother; 2019 Aug; 53(8):812-832. PubMed ID: 30770025 [No Abstract] [Full Text] [Related]
15. Managing oncology research protocols. Lunik MC Top Hosp Pharm Manage; 1994 Jul; 14(2):11-21. PubMed ID: 10136201 [TBL] [Abstract][Full Text] [Related]
16. Drug-drug interactions in pediatric oncology patients. Balk TE; van der Sijs IH; van Gelder T; Janssen JJB; van der Sluis IM; van Leeuwen RWF; Engels FK Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28205376 [TBL] [Abstract][Full Text] [Related]
17. Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer: A Prospective Study of Medication Surveillance. Ramos-Esquivel A; Víquez-Jaikel Á; Fernández C J Oncol Pract; 2017 Jul; 13(7):e613-e622. PubMed ID: 28628392 [TBL] [Abstract][Full Text] [Related]
18. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. van Leeuwen RWF; Jansman FGA; van den Bemt PMLA; de Man F; Piran F; Vincenten I; Jager A; Rijneveld AW; Brugma JD; Mathijssen RHJ; van Gelder T Ann Oncol; 2015 May; 26(5):992-997. PubMed ID: 25628444 [TBL] [Abstract][Full Text] [Related]
19. Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections. Kim J; Singh H; Ayalew K; Borror K; Campbell M; Johnson LL; Karesh A; Khin NA; Less JR; Menikoff J; Minasian L; Mitchell SA; Papadopoulos EJ; Piekarz RL; Prohaska KA; Thompson S; Sridhara R; Pazdur R; Kluetz PG Clin Cancer Res; 2018 Apr; 24(8):1780-1784. PubMed ID: 29237718 [TBL] [Abstract][Full Text] [Related]
20. The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software. Nightingale G; Pizzi LT; Barlow A; Barlow B; Jacisin T; McGuire M; Swartz K; Chapman A J Geriatr Oncol; 2018 Sep; 9(5):526-533. PubMed ID: 29510896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]